255 related articles for article (PubMed ID: 34100235)
1. Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.
Cromer SJ; D'Silva KM; Yu EW; Landon J; Desai RJ; Kim SC
J Gen Intern Med; 2022 Jun; 37(8):1917-1924. PubMed ID: 34100235
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of osteoporosis treatments in Germany.
O'Kelly J; Bartsch R; Kossack N; Borchert J; Pignot M; Hadji P
Arch Osteoporos; 2022 Aug; 17(1):119. PubMed ID: 36044096
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
[TBL] [Abstract][Full Text] [Related]
5. Polypharmacy in Osteoporosis Treatment.
McConnell M; Shieh A
Clin Geriatr Med; 2022 Nov; 38(4):715-726. PubMed ID: 36210087
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.
Marques A; Lourenço Ó; Ortsäter G; Borgström F; Kanis JA; da Silva JA
Calcif Tissue Int; 2016 Aug; 99(2):131-41. PubMed ID: 27016370
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan.
Mori T; Crandall CJ; Fujii T; Ganz DA
Arch Osteoporos; 2021 Jul; 16(1):113. PubMed ID: 34264429
[TBL] [Abstract][Full Text] [Related]
8. Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study.
Wu CH; Li CC; Hsu YH; Liang FW; Chang YF; Hwang JS
J Clin Endocrinol Metab; 2023 Mar; 108(4):827-833. PubMed ID: 36317591
[TBL] [Abstract][Full Text] [Related]
9. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Albert SG; Reddy S
Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
[TBL] [Abstract][Full Text] [Related]
10. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
[TBL] [Abstract][Full Text] [Related]
12. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
Yoshizawa T; Nishino T; Okubo I; Yamazaki M
Arch Osteoporos; 2018 Aug; 13(1):94. PubMed ID: 30159632
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study.
Viggers R; Al-Mashhadi Z; Starup-Linde J; Vestergaard P
Front Endocrinol (Lausanne); 2021; 12():826997. PubMed ID: 35154013
[TBL] [Abstract][Full Text] [Related]
15. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
Anastasilakis AD; Polyzos SA; Makras P
Eur J Endocrinol; 2018 Jul; 179(1):R31-R45. PubMed ID: 29691303
[TBL] [Abstract][Full Text] [Related]
16. Denosumab versus zoledronic acid in elderly patients after hip fracture.
Kim SJ; Kim JW; Lee DW
J Orthop Surg (Hong Kong); 2022; 30(3):10225536221147082. PubMed ID: 36541833
[TBL] [Abstract][Full Text] [Related]
17. Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.
Lehmann T; Aeberli D
Osteoporos Int; 2017 Oct; 28(10):3067-3068. PubMed ID: 28589418
[No Abstract] [Full Text] [Related]
18. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
19. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China).
Tan X; Wen F; Yang W; Xie JY; Ding LL; Mo YX
Menopause; 2019 Aug; 26(8):929-939. PubMed ID: 31021904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
